Who are Immunovant, Inc.'s main suppliers?

Immunovant, Inc. (IMVT) key suppliers include: CROS, VENDORS, HANALL, argenx SE, argenx SE and 6 more. View the full supplier network at chainsifter.com/chain/IMVT.

Who are Immunovant, Inc.'s major customers?

Immunovant, Inc. (IMVT) key customers include: argenx SE, argenx SE, Johnson & Johnson, Johnson & Johnson, Sanofi and 1 more. View the full customer network at chainsifter.com/chain/IMVT.

What sector is Immunovant, Inc. in?

Immunovant, Inc. (IMVT) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

IMVT Supply Chain: Immunovant, Inc. Supplier List & 19 Relationships

11Suppliers

6Customers

2Debt Items

20Related Chains

Immunovant, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CROS	CROS	90%	In the normal course of business, the Company enters into agreements with CROs for clinical trials
VENDORS	VENDORS	90%	In the normal course of business, the Company enters into agreements with CROs for clinical trials and with vendors for nonclinical studies, manufacturing and other services and products for operatin…
HANALL	HANALL	80%	We have licensed certain intellectual property rights, including certain intellectual property rights covering IMVT-1402 and batoclimab from HanAll
ARGX	argenx SE	72%	Reciprocal relationship from ARGX graph: Reciprocal relationship from IMVT graph: gulated, unapproved and off-label treatments. Even if a biosimilar product is less effective than our product candida…
ARGX	argenx SE	72%	gulated, unapproved and off-label treatments. Even if a biosimilar product is less effective than our product candidates, a less effective biosimilar may be more quickly adopted by physicians and pat…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from IMVT graph: gulated, unapproved and off-label treatments. Even if a biosimilar product is less effective than our product candidat…
JNJ	Johnson & Johnson	72%	gulated, unapproved and off-label treatments. Even if a biosimilar product is less effective than our product candidates, a less effective biosimilar may be more quickly adopted by physicians and pat…
ROIV	Roivant Sciences Ltd.	72%	Reciprocal relationship from ROIV graph: Reciprocal relationship from IMVT graph: Reciprocal relationship from ROIV graph: Reciprocal relationship from IMVT graph: data from our clinical trials that …
ROIV	Roivant Sciences Ltd.	72%	data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in …
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMVT graph: gulated, unapproved and off-label treatments. Even if a biosimilar product is less effective than our product candid…
SNYNF	Sanofi	72%	gulated, unapproved and off-label treatments. Even if a biosimilar product is less effective than our product candidates, a less effective biosimilar may be more quickly adopted by physicians and pat…

Immunovant, Inc. Customers

Ticker	Name	Confidence	Evidence
ARGX	argenx SE	72%	gulated, unapproved and off-label treatments. Even if a biosimilar product is less effective than our product candidates, a less effective biosimilar may be more quickly adopted by physicians and pat…
ARGX	argenx SE	72%	Reciprocal relationship from ARGX graph: Reciprocal relationship from IMVT graph: gulated, unapproved and off-label treatments. Even if a biosimilar product is less effective than our product candida…
JNJ	Johnson & Johnson	72%	gulated, unapproved and off-label treatments. Even if a biosimilar product is less effective than our product candidates, a less effective biosimilar may be more quickly adopted by physicians and pat…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from IMVT graph: gulated, unapproved and off-label treatments. Even if a biosimilar product is less effective than our product candidat…
SNYNF	Sanofi	72%	gulated, unapproved and off-label treatments. Even if a biosimilar product is less effective than our product candidates, a less effective biosimilar may be more quickly adopted by physicians and pat…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMVT graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMVT graph: Reciprocal relationship from SNYN…

Immunovant, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
IMVT-DEBT-10258	Warrants outstanding: 0	90%	xbrl warrant detail from xbrl 2021-03-31.
IMVT-DEBT-10259	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2020-03-31.

Immunovant, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Immunovant, Inc..

Immunovant, Inc. Ownership

Holder	Name	Confidence	Evidence
IMVT-OWNER-FMR-LLC	FMR LLC	90%	13F overlay lists FMR LLC as top holder; 218 tracked holders.

Immunovant, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
BNTX	BioNTech SE	100.00	2
ARGX	argenx SE	100.00	1	['customer', 'supplier']
SNYNF	Sanofi	100.00	1	['customer', 'supplier']
ECO	Okeanis Eco Tankers Corp.	100.00	2
JNJ	Johnson & Johnson	100.00	1	['customer', 'supplier']
CVRX	CVRx, Inc.	50.00	2
CYCN	Cyclerion Therapeutics, Inc.	50.00	2
WHWK	Whitehawk Therapeutics, Inc.	50.00	2
ANL	Adlai Nortye Ltd.	50.00	2
ANIK	Anika Therapeutics, Inc.	50.00	2
ANRO	Alto Neuroscience, Inc.	50.00	2
AORT	Artivion, Inc.	50.00	2
AVBP	ArriVent BioPharma, Inc.	50.00	2
CRVS	Corvus Pharmaceuticals, Inc.	50.00	2
ALXO	ALX Oncology Holdings Inc.	50.00	2
CBIO	Crescent Biopharma, Inc.	50.00	2
CBIH	Cannabis Bioscience International Holdings, Inc.	50.00	2
CTMX	CytomX Therapeutics, Inc.	50.00	2
RXRX	Recursion Pharmaceuticals, Inc.	50.00	2
CYTK	Cytokinetics, Incorporated	50.00	2

Immunovant, Inc. Supply Chain